- Home
- NEGG vs KALV Comparison
NEGG vs KALV Comparison
Compare NEGG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | KALV |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 1.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NEGG | KALV |
|---|---|---|
| Price | $43.99 | $20.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 53.9K | ★ 1.0M |
| Earning Date | 04-24-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $187.19 |
| Revenue Next Year | N/A | $54.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $3.32 | $9.83 |
| 52 Week High | $137.84 | $21.31 |
Technical Indicators
Market Signals| Indicator | NEGG | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 63.23 |
| Support Level | $42.41 | $14.66 |
| Resistance Level | $47.15 | $21.31 |
| Average True Range (ATR) | 3.77 | 1.37 |
| MACD | 0.65 | 0.04 |
| Stochastic Oscillator | 69.62 | 82.01 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.